Back to results
US 10,117,909 B2Granted
Combination of an insulin and a GLP-1 agonist
AssigneeSanofi-Aventis Deutschland GmbH
InventorsUlrich Werner, Barbel Rotthauser
Life of this patent
Estimating the term…
Abstract
The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
Claims8
A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
- (a) insulin glargine or a pharmaceutically acceptable salt thereof, and
- (b) desPro36exendin-4(1-39)-Lys6-NH2 (AVE0010) or a pharmaceutically acceptable salt thereof;
- wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 33 μg/mL;
- and
- wherein the prefilled syringe is configured to administer the pharmaceutical formulation at a dosage of insulin glargine between about 15 units and about 80 units and a dosage of AVE0010 between about 5 μg and about 2 mg.
2 more elements
A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
- (a) insulin glargine or a pharmaceutically acceptable salt thereof, and
- (b) desPro36exendin-4(1-39)-Lys6-NH2 (AVE0010) or a pharmaceutically acceptable salt thereof;
- wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL and a concentration of AVE0010 that is about 20 m/ml to about 150 μg/ml.
A prefilled syringe comprising a pharmaceutical formulation, wherein the pharmaceutical formulation comprises a combination of:
- (a) insulin glargine or a pharmaceutically acceptable salt thereof, and
- (b) desPro36exendin-4(1-39)-Lys6-NH2 (AVE0010) or a pharmaceutically acceptable salt thereof;
- wherein the pharmaceutical formulation has a concentration of insulin glargine that is about 100 units/mL, and
- wherein the ratio of insulin glargine and AVE0010 in the pharmaceutical formulation is about 1.5 units to about 4 units of insulin glargine to 1 μg of AVE0010.
1 more element
Dependencies are inferred from the claim text.